Stock Analiz

Jazz Pharmaceuticals plc (JAZZ) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Jazz Pharmaceuticals’s revenue went from $1.5B in fiscal 2016 to $4.3B in fiscal 2025, growth of about 12.4% a year.

Net income in fiscal 2025 was -$356M, a net margin of -8.3%; the best year in this period was 2024 with $560M.

Over the twelve months to September 30, 2026, revenue was $4.7B and net income $206M.

Free cash flow was $1.3B in fiscal 2025 and positive in 10 of the 10 years shown.

Revenue, profit and cash flow by year

Revenue
2016: $1.5B162017: $1.6B172018: $1.9B182019: $2.2B192020: $2.4B202021: $3.1B212022: $3.7B222023: $3.8B232024: $4.1B242025: $4.3B25$4.3B
Net income
2016: $397M162017: $488M172018: $447M182019: $523M192020: $239M202021: -$330M212022: -$224M222023: $415M232024: $560M242025: -$356M25-$356M
Free cash flow
2016: $583M162017: $664M172018: $779M182019: $736M192020: $885M202021: $751M212022: $1.2B222023: $1.1B232024: $1.4B242025: $1.3B25$1.3B
EPS (diluted)
2016: $6.41162017: $7.96172018: $7.30182019: $9.09192020: $4.22202021: $-5.52212022: $-3.58222023: $6.10232024: $8.65242025: $-5.8425$-5.84

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$4.7B$4.3B$4.1B$3.8B$3.7B$3.1B$2.4B$2.2B$1.9B$1.6B$1.5B
Gross profit———————————
Operating income$426M-$430M$717M$579M-$66M$170M$378M$532M$615M$529M$592M
Net income$206M-$356M$560M$415M-$224M-$330M$239M$523M$447M$488M$397M
EPS (diluted)$3.38$-5.84$8.65$6.10$-3.58$-5.52$4.22$9.09$7.30$7.96$6.41
R&D$829M$783M$884M$850M$590M$506M$335M$300M$227M$198M$162M
Revenue growth—+4.9%+6.1%+4.8%+18.3%+30.9%+9.3%+14.3%+16.8%+8.8%+12.3%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$1.7B$1.4B$1.4B$1.1B$1.3B$779M$900M$776M$799M$693M$592M
Capital spending-$71M-$59M-$38M-$24M-$29M-$28M-$15M-$40M-$20M-$29M-$10M
Free cash flow$1.6B$1.3B$1.4B$1.1B$1.2B$751M$885M$736M$779M$664M$583M
Dividends paid—$0$0$0$0$0$0$0$0$0—
Buybacks$225M$125M$311M$270M$54000$0$147M$301M$524M$99M$278M
Stock-based pay$296M$291M$248M$227M$222M$189M$121M$111M$102M$107M$99M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$1.4B$2.4B$1.5B$881M$591M$1.1B$637M$310M$386M$366M
Debt—$5.4B$6.2B$5.8B$5.8B$6.2B$2.2B$1.8B$1.7B$1.6B$2.0B
Equity—$4.3B$4.1B$3.7B$3.1B$4.0B$3.7B$3.1B$2.8B$2.7B$1.9B
Total assets—$11.7B$12.0B$11.4B$10.8B$12.3B$6.5B$5.5B$5.2B$5.1B$4.8B
Shares (diluted)65M61M66M72M63M60M57M58M61M61M62M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin———————————
Operating margin9.0%-10.1%17.6%15.1%-1.8%5.5%16.0%24.6%32.5%32.7%39.8%
Net margin4.4%-8.3%13.8%10.8%-6.1%-10.7%10.1%24.2%23.6%30.1%26.7%
FCF margin34.4%30.4%33.4%27.9%34.0%24.3%37.4%34.1%41.2%41.0%39.2%
ROIC—-2.5%5.5%4.8%-0.4%1.3%5.6%8.6%11.6%9.7%11.3%
ROE—-8.2%13.7%11.1%-7.3%-8.3%6.5%16.8%16.2%18.0%21.1%

Frequently asked questions

What is Jazz Pharmaceuticals’s annual revenue?

$4.3B in fiscal 2025 and $4.7B over the twelve months to September 30, 2026.

How much profit does Jazz Pharmaceuticals make?

Net income was -$356M in fiscal 2025 (net margin -8.3%).

Is Jazz Pharmaceuticals’s revenue growing?

Yes: revenue rose 4.9% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.